Case of Ceftriaxone-Induced Immune Hemolytic Anemia in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Unit
Jaslyn Maurer, Samantha Ruddy, Monica Bapna, George Rodriguez, Sorana Segal-Maurer
International Journal of Medical and Pharmaceutical Case Reports · pp. 93–98 · Published 13 Dec 2023
10.9734/ijmpcr/2023/v16i4357Abstract
Background: Ceftriaxone is a commonly used antimicrobial agent for the treatment of various infections. It is frequently administered once daily and is an attractive option for use in both in- and out-patient settings. Ceftriaxone-induced immune hemolytic anemia, while rare, can potentially cause severe and even fatal complications if not identified and managed early. Case Presentation: We present the case of a 59-year-old Korean female with hypertension, hyperlipidemia, diabetes, and no known prior allergies, who was being treated for pyelonephritis in our outpatient parenteral antimicrobial therapy (OPAT) infusion unit with ceftriaxone. A few days following antibiotic exposure she was admitted to the hospital and her laboratory values were most consistent with hemolysis. All values normalized following discontinuation of ceftriaxone and initiation of ertapenem. Conclusion: This case describes the clinical course, alternative diagnosis as well as the severity of ceftriaxone induced immune hemolytic anemia. While a rare phenomenon, it can be potentially fatal. Furthermore, it validates the importance of prompt identification and withdrawal of the offending agent may limit the progression of this disease, especially in the outpatient setting, where patients are not as closely monitored.
References (8)
- 1 Immune hemolytic anemia associated with drug therapy [DOI]
- 2 Immune Hemolytic Anemias [DOI]
- 3 Drug-induced immune hemolytic anemia [DOI]
- 4 Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature [DOI]
- 5 Ceftriaxone-Induced Immune Hemolytic Anemia [DOI]
- 6 Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report [DOI]
- 7 Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin [DOI]
- 8 Severe drug-induced immune haemolytic anaemia due to ceftazidime. [DOI]
Cited by 2
Sonja Miotti, Giada Wyttenbach, Mario G. Bianchetti · British Journal of Clinical Pharmacology · 2026
Showing 1 of 2 known citations — external sources report more than can currently be individually listed.
Related research
- Typhoid Fever: Azithromycin vs. Ceftriaxone for the Treatment of Mild to Moderate Cases in Children — shares topic coverage
- Adverse Reaction to Ceftriaxone: How Far Can We Go to exclude an Allergy? — shares topic coverage
- Retro-respective Evaluation of New Fixed Dose Combination of Antibiotics in Management of Severe Skin and Soft Tissue Infections – A Comparative Pharmacoeconomic Study — shares topic coverage
- Ceftriaxone Improves Neuron Protection and Functional Recovery in Rat Model of Spinal Cord Injury — shares topic coverage
- Multidrug Resistant Salmonella enterica Strains in South Western Nigeria: Prevalence and Susceptibility to Ceftriaxone — shares topic coverage
Article metrics
Real usage data collected on this platform.
22
Page views
0
PDF downloads
3
Outbound clicks
2
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.